SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population
University Hospital, Angers
502 participants
Oct 20, 2023
INTERVENTIONAL
Conditions
Summary
The main objective of the study is to evaluate the pertinence of initiating screening for advanced hepatic fibrosis after a FIB4 result \> 2.67 automatically calculated in the local laboratory and followed by a specialized hepatic evaluation.
Eligibility
Inclusion Criteria5
- Age between 18 and 70 years
- Blood sample taken at a medical testing laboratory selected for the study.
- Biology without high risk of false positive result for FIB4 (AST and ALT ≤ 300 IU/l ; Platelets ≥ 50 G/l and \< 500 G/l.)
- FIB4 \> 2.67 after automatic calculation in the medical laboratory less than 3 months old
- Signature of informed consent to participate in the study
Exclusion Criteria7
- Ongoing specialized follow-up for a chronic liver disease
- Difficulty understanding the French language
- Pregnant women, breastfeeding or parturient women
- Persons suspended from liberty by judicial or administrative decision
- Persons under legal protection
- Persons unable to express their consent
- Non affiliation to a social security system
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Diagnostic procedure : FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05880173